Nucleic Acid Preparations Identify Norovirus and Mycoplasma pneumonia
|
By LabMedica International staff writers Posted on 15 Oct 2013 |

Image: DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of Norovirus and Mycoplasma pneumonia.
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Project Aims to Develop First Single-Cell Assay for ADC Therapies
Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more








